Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Cathy Kelly

Senior Writer

Washington, DC
Cathy Kelly has been covering reimbursement and market access news for more than a decade for "The Pink Sheet" and other publications that are now part of Informa's pharmaceutical intelligence resources. Her expertise spans legislative, regulatory and public policy topics as well as coverage trends in public and private insurance markets. Cathy is especially interested in following the ongoing transformation of the US health care system and its effect upon major stakeholders in the biopharma industry. She is based in Washington D.C.
Advertisement
Set Alert for Articles By Cathy Kelly

Latest From Cathy Kelly

Part D Reforms: Concerns With Specialty Cost Sharing, Merging Part B Coverage Raised

BIO comments respond to the Centers for Medicare and Medicaid Services' call for input on ways to improve the Medicare Part D program.

Policy Medicare

Express Scripts-Anthem Split Could Signal Positive Trend For Biopharma

Express Scripts is losing its biggest customer, which could be a sign that plan sponsors are looking for more control over their pharmacy spending -- bad news for the big PBMs but good news for biopharma?

Pharmacy Benefit Management Pricing Debate

What's At Stake: Biopharma Profit Growth Reliant On Price Increases

Price increases generated 100% of net US earnings growth at major biopharma firms in 2016, according to investment analyst report assessing threat of continued pricing pressure.

Pricing Debate Pharmacy Benefit Management

Drug Prices: How US FDA Can Foster Competition Beyond Generic Approvals

Former FDA Commissioner von Eschenbach and Project HOPE's Wilensky offer related views on how the government could more proactively promote competition with drugs like Shkreli's Daraprim.

Policy Pricing Debate

Formulary Oversight For Obamacare Plans Will Be Deferred In Some States

Patient groups raise concerns that states may not be able to monitor formularies for discrimination, limiting patient access to drug coverage.

Policy Government Payers

Drug Pricing Pundit Gottlieb Likely To Stay In His Lane At FDA

FDA commissioner-nominee Scott Gottlieb is expected to steer clear of pricing issues at the agency, despite his reputation as a thought leader on the issue.

Policy Pricing Debate
See All
Advertisement
UsernamePublicRestriction

Register